GlassScriptPhysician profile
Anne Dempsey
NPI 1134557861
$4,435.87
in general payments reported to CMS, 2019-2025
23 companies · $1,391 in 2025
The $1,391 reported for 2025 was more than what 89% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $382 · 2022: $797 · 2023: $803 · 2024: $1,064 · 2025: $1,391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,251 · Education: $6.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,250.93 |
| Education | $6.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,082.20 | 2021-2025 | Reveal Linq, Linq II, Symplicity G3 |
| E.R. Squibb & Sons, L.L.C. | $629.06 | 2021-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $484.58 | 2021-2025 | Jardiance |
| Pfizer INC. | $274.89 | 2022-2025 | |
| Boston Scientific Corporation | $254.73 | 2021-2025 | Watchman Flx, Cds - Mct/Cem Monitoring |
| Janssen Pharmaceuticals, INC | $251.41 | 2023-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $199.42 | 2021-2025 | Breztri |
| Amgen INC. | $179.62 | 2021-2025 | Repatha, Repatha |
| Atricure, INC. | $172.80 | 2022 | |
| Novartis Pharmaceuticals Corporation | $137.63 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $123.97 | 2025 | |
| Philips North America LLC | $108.03 | 2022-2025 | Extended Holter, (Ck7) Extended Holter |
| Abbott Laboratories | $106.79 | 2022-2025 | Diamondback Coronary |
| Actelion Pharmaceuticals US, INC. | $96.18 | 2025 | Opsumit |
| Scpharmaceuticals INC. | $95.56 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $44.41 | 2023-2024 | Ozempic, Rybelsus |
| Regeneron Healthcare Solutions, INC. | $36.46 | 2023 | Evkeeza |
| Azurity Pharmaceuticals, INC. | $36.43 | 2024-2025 | Horizant |
| Esperion Therapeutics, INC. | $35.18 | 2025 | Nexletol |
| Edwards Lifesciences Corporation | $33.58 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $24.87 | 2024 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.19 | 2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $12.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Dempsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.